Laboratoires A-Derma, Pierre Fabre Dermo-Cosmétique, Lavaur, France.
Pierre Fabre Dermo-Cosmétique, Research & Development, Evaluation Department, Toulouse, France.
J Eur Acad Dermatol Venereol. 2024 Aug;38 Suppl 7:12-20. doi: 10.1111/jdv.19876.
Acne vulgaris is a common chronic inflammatory disorder of the pilosebaceous unit, characterized by papules, pustules and/or nodules manifesting primarily on the face and/or upper back that can leave scars, post-inflammatory hyperpigmentation (PIH) and erythema (PIE).
To evaluate the anti-inflammatory properties of a protein-free sap extruded from Rhealba® oat plantlets and a Garcinia mangostana extract on Cutibacterium acnes-induced inflammation in vitro and assess the tolerability and efficacy of a dermocosmetic product containing these actives in subjects with mild-to-moderate acne.
Monocyte-derived dendritic cells (Mo-DCs) from acne patients were stimulated with a planktonic culture of C. acnes and cytokine production was evaluated before and after addition of the test extracts by RT-PCR and ELISA. The clinical study was conducted in subjects with mild-to-moderate acne who applied the product to their face and upper back twice-daily for 2 months.
Cutibacterium acnes-induced IL-6, IL-12p40, IL-10 and TNFα synthesis was reduced by the addition of the Garcinia mangostana extract and oat sap in vitro. The clinical study included 54 subjects. The 2-month, twice-daily application of the test product to the whole face and acne-affected areas on the upper back was well tolerated. It led to significant decreases in the number of retentional (-21% for 69% of subjects at D57) and inflammatory (-35% for 79% of subjects at D57) acne lesions, as well as a decrease in Global Acne Evaluation severity scores (2.5 at D1, 2.2 at D29 and 2.1 at D57). The dermatologist also rated the product as effective or very effective in most subjects with PIE (82%; n = 33/40) and PIH (70%; n = 8/11) at D57.
The actives demonstrated anti-inflammatory effects in vitro, and the dermocosmetic product showed good clinical efficacy and tolerability in subjects with mild-to-moderate acne, supporting the use of this product in acne management.
寻常痤疮是一种常见的慢性炎症性毛囊皮脂腺疾病,表现为丘疹、脓疱和/或结节,主要发生在面部和/或上背部,可留下疤痕、炎症后色素沉着(PIH)和红斑(PIE)。
评估从 Rhealba®燕麦苗中提取的无蛋白汁液和藤黄果提取物对痤疮丙酸杆菌诱导的炎症的抗炎特性,并评估含有这些活性成分的皮肤护理产品在轻中度痤疮患者中的耐受性和疗效。
用痤疮丙酸杆菌浮游培养物刺激痤疮患者来源的单核细胞衍生树突状细胞(Mo-DC),并用 RT-PCR 和 ELISA 评估添加测试提取物前后细胞因子的产生。临床研究在轻中度痤疮患者中进行,他们每天两次将产品涂抹于面部和上背部,为期 2 个月。
体外研究表明,藤黄果提取物和燕麦汁液可减少痤疮丙酸杆菌诱导的 IL-6、IL-12p40、IL-10 和 TNFα 的合成。临床研究共纳入 54 例患者。整个面部和上背部痤疮病变区域每天两次应用受试产品 2 个月,患者耐受性良好。它导致粉刺皮损数量(对 69%的患者,57 天Retentional 减少 21%)和炎症性皮损数量(对 79%的患者,57 天减少 35%)显著减少,全球痤疮评估严重程度评分也降低(第 1 天 2.5,第 29 天 2.2,第 57 天 2.1)。皮肤科医生还在第 57 天对 PIE(82%,n=33/40)和 PIH(70%,n=8/11)的大多数患者评估该产品为有效或非常有效。
这些活性物质在体外显示出抗炎作用,皮肤护理产品在轻中度痤疮患者中表现出良好的临床疗效和耐受性,支持在痤疮管理中使用该产品。